Skip to content

Twitter page opens in new window Linkedin page opens in new window Instagram page opens in new window

info@pharmaust.com+61 8 9202 6814

PharmAust (PAA)

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

Daily Archives: December 17, 2018

Top 20 Shareholders 14 December 2018

News & Announcements 2018By Richard Mollard December 17, 2018

Top_Holders_Report (14)Download

Recent Articles

200921_PharmAust Awarded FightMND Grant for Phase I Trial
September 21, 2020
14 September, Shareholder Update
September 14, 2020
Elanco not to Exercise Agreed Option
September 9, 2020
Monepantel Anti-Covid-19 Activity Confirmed
September 9, 2020

MENU

Home
About Us
Pipeline & Trials
Investor Centre
Media
Contact Us

SUBSCRIBE TO OUR NEWSLETTER

Leave this field empty if you're human:

TWITTER

PharmAustFollow

Retweet on Twitter PharmAust Retweeted

The Market Herald @themarketherald·

PharmAust (PAA) has been granted $881,085 for a phase one clinical trial of monepantel in patients with Motor Neurone Disease (MND).
--
https://buff.ly/32Nvu44

#themarketherald #asxnews #asx #asx200 #asxtoday #ausstocks #ausbiz $PAA $PAA.AX

Reply on Twitter 1307920108770164736 Retweet on Twitter 13079201087701647362 Like on Twitter 13079201087701647363 Twitter 1307920108770164736

Copyright © 2020 Pharmaust. All rights reserved.

Website Design & Digital Marketing Perth by Total Click Solutions